Research Paper Volume 16, Issue 6 pp 4980—4999

CMS121: a novel approach to mitigate aging-related obesity and metabolic dysfunction

class="figure-viewer-img"

Figure 1. Nutritional, body mass, locomotor activity, and metabolic activity of mice fed a control diet or a diet containing the geroneuroprotective drug candidate CMS121 for 6 months. Beginning at the 5th week after birth, mice were either kept on the control diet (CTL) or put on a diet containing CMS121 ad libitum. Cumulative food intake (A) and body weight (B). Food intake per animal was based on the average food consumption in cages holding 3 mice allocated among a total of 4 cages, and the body weight of 12 mice was followed. Differences between linear regression slopes of CTL and CMS121-treated mice were analyzed and the p-values are shown. Initial and final body weights are presented (C). During the 13th week of treatment body mass (n = 12) indexes were obtained: lean mass (D), and fat mass (E). Metabolic activity (FH) was evaluated at the 15th week of treatment for oxygen consumption (VO2) (F); carbon dioxide production (VCO2) (G); respiratory exchange ratio (RER) (H), and ambulatory activity (I); Data are presented as mean ± SD (n = 4). Bold underlined p-values indicate statistical differences.